このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

選択的骨髄増殖性腫瘍患者を対象としたPRT12396の第1相臨床試験

2026年10月28日 更新者:Prelude Therapeutics Incorporated

PRT12396の真性多血症および骨髄線維症患者を対象とした第1相、オープンラベル、多施設共同、安全性および有効性試験

This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).

調査の概要

詳細な説明

This first-in-human, open-label, multi-center Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF). Eligible MF populations include participants with intermediate-1, intermediate-2, or high-risk primary MF, as well as post-polycythemia vera MF or post-essential thrombocythemia MF, with evidence of disease burden based on splenomegaly.

The study is conducted in two parts:

Part 1 (dose escalation) evaluates escalating oral doses of PRT12396 to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]).

Part 2 (dose expansion) enrolls additional participants at selected dose level(s) to further characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in the PV and MF populations.

Approximately up to 100 participants are planned for enrollment across both parts of the study.

研究の種類

介入

入学 (推定)

100

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • California
      • Los Angeles、California、アメリカ、90095
        • 募集
        • UCLA Ronald Reagan Medical Center
      • Sacramento、California、アメリカ、95817
        • 募集
        • University of California, Davis Comprehensive Cancer Center
    • Colorado
      • Denver、Colorado、アメリカ、80218
        • 募集
        • Colorado Blood Cancer Institute
    • Florida
      • Coral Springs、Florida、アメリカ、33065
        • 募集
        • BRCR Global - Coral Springs
      • Miami、Florida、アメリカ、33136
        • 募集
        • Sylvester Comprehensive Cancer Center
      • Tampa、Florida、アメリカ、33612
        • 募集
        • Moffitt Cancer Center
    • Michigan
      • Grand Rapids、Michigan、アメリカ、49546
        • 募集
        • START Midwest, LLC
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19107
        • 募集
        • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office
    • Tennessee
      • Nashville、Tennessee、アメリカ、37203
        • 募集
        • Tristar BMT
      • Nashville、Tennessee、アメリカ、37203
        • 募集
        • Tennessee Oncology, PLLC - Investigational Drug Services
    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • The University of Texas, MD Anderson Cancer Center
      • Florence、イタリア、50134
        • 募集
        • Azienda Ospedaliero Universitaria Careggi
    • South Australia
      • Adelaide、South Australia、オーストラリア、5000
        • 募集
        • Royal Adelaide Hospital
    • Victoria
      • Clayton、Victoria、オーストラリア、3168
        • 募集
        • Monash Health, Monash Medical Centre
    • Western Australia
      • Nedlands、Western Australia、オーストラリア、6009
        • 募集
        • One Clinical Research
      • Barcelona、スペイン、08036
        • 募集
        • Hospital Clinic de Barcelona
      • Madrid、スペイン、28034
        • 募集
        • Hospital Universitario Ramon y Cajal
      • Madrid、スペイン、28041
        • 募集
        • Hospital Universitario 12 de Octubre
      • Valencia、スペイン、46010
        • 募集
        • Hospital Clínico Universitario de Valencia
      • Nice、フランス、06200
        • 募集
        • Nice University Medicâl Center (CHU Nice, Hôpital Archet 1)
      • Paris、フランス、75010
        • 募集
        • Saint-Louis Hospital
      • Toulouse、フランス、31059
        • 募集
        • Oncopole Claudius Regaud

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures.
  • Confirmed diagnosis of PV or MF according to WHO 2016 or revised ICC/WHO 2022 criteria
  • Documented presence of a JAK2 V617 mutation
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Estimate life expectancy of ≥12 weeks per investigator assessment.
  • Negative serum or urine pregnancy test and agree to use contraception or maintain true abstinence.
  • Adequate organ function and bone marrow reserves (hematology, renal, and hepatic)

Exclusion Criteria:

  • History of another malignancy within 3 years prior to enrollment, except for malignancy considered cured with low risk of recurrence.
  • Clinically significant anemia due to nutritional deficiency or hemolytic disorders.
  • Active or uncontrolled infection requiring systemic therapy or hospitalization.
  • Any other medical or psychiatric conditions that, in the Investigator's judgment, would increase risk or interfere with study participation or interpretation of results.
  • Clinically significant or uncontrolled medical conditions, including active infection or cardiovascular disease, that would increase risk or interfere with study participation.
  • Unresolved toxicity Grade >1 from prior anticancer therapy, except for alopecia or peripheral neuropathy Grade ≤2.
  • Pregnancy or breastfeeding
  • Known sensitivity or contraindication to any component of study, or the excipients of study treatment.
  • Prior systemic therapy for PV or MF, prior or planned allogeneic hematopoietic stem-cell transplantation, recent major surgery, prior splenectomy or prior splenic irradiation, or use of hematopoietic growth factors within protocol-defined washout periods.
  • Use of strong or moderate cytochrome P450 (CYP) 3A4 inhibitor or inducer, sensitive CYP3A substrates with narrow therapeutic range, or acid-reducing agents that cannot be discontinued prior to study treatment.
  • Participation in another interventional clinical study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:PRT12396: MF

Participants with myelofibrosis receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE)

PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals.

実験的:PRT12396: PV

Participants with polycythemia vera receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE)

PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Dose limiting toxicity (DLT) of PRT12396
時間枠:Through cycle 1 (4 weeks)

Incidence of dose limiting toxicities, defined according to protocol-specified criteria

Through cycle 1 (4 weeks)
Incidence and severity of Adverse events
時間枠:Through study completion, an average of 2 years

Incidence and severity of treatment-emergent adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 6.0

Through study completion, an average of 2 years
Adverse Events Leading to Dose Modifications or Discontinuation
時間枠:Through study completion, an average of 2 years

Incidence of AEs leading to dose reductions, dose interruptions, treatment discontinuations, and clinically significant laboratory abnormalities

Through study completion, an average of 2 years
Maximum tolerated dose (MTD) and Recommended Dose(s) for Expansion (RDE[s]) of PRT12396
時間枠:Through study completion, an average of 2 years

Determination of the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]) based on evaluation of DLTs, safety, and tolerability data

Through study completion, an average of 2 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Hematologic Response Rate (PV)
時間枠:Through study completion, an average of 2 years

Proportion of participants with polycythemia vera (PV) achieving best overall hematologic response (complete hematologic response or partial hematologic response) from the overall response assessments by Investigator

Through study completion, an average of 2 years
Duration of Hematologic Response (PV)
時間枠:Through study completion, an average of 2 years

Duration of hematologic response in PV participants, defined as the time from first documented response (best overall hematologic response) to disease progression or death, whichever comes first

Through study completion, an average of 2 years
Hematocrit Control Without Phlebotomy Requirements (PV)
時間枠:Through study completion, an average of 2 years

Proportion of PV participants achieving and maintaining hematocrit control without phlebotomy, time to first phlebotomy, and frequency of phlebotomy

Through study completion, an average of 2 years
Spleen Response (MF)
時間枠:Through study completion, an average of 2 years

Assessment of spleen response including proportion achieving protocol-specified reduction in spleen volume, time to spleen response, duration of spleen response, and reduction in palpable spleen length

Through study completion, an average of 2 years
Change from Baseline in Hemoglobin (MF)
時間枠:Through study completion, an average of 2 years

Change from baseline in hemoglobin levels in MF participants

Through study completion, an average of 2 years
Change from Baseline in Platelet Count (MF)
時間枠:Through study completion, an average of 2 years

Change from baseline in platelet count in MF participants

Through study completion, an average of 2 years
Change from Baseline in Absolute Neutrophil Count (MF)
時間枠:Through study completion, an average of 2 years

Change from baseline in absolute neutrophil count in MF participants

Through study completion, an average of 2 years
Transfusion Independence (MF)
時間枠:Through study completion, an average of 2 years

Proportion achieving transfusion independence and duration of transfusion independence as defined by protocol criteria

Through study completion, an average of 2 years
Maximum Observed Plasma Concentration (Cmax)
時間枠:Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Maximum observed plasma concentration will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Time To Maximum Concentration (Tmax)
時間枠:Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Time to maximum concentration will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Area under the plasma concentration versus time curve (AUC)
時間枠:Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Area under the plasma concentration-time curve will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Terminal Elimination Half-life (T1/2)
時間枠:Cycle 1 Day 1

Terminal elimination half-life will be calculated using non-compartmental analysis

Cycle 1 Day 1
Steady State Trough Concentrations
時間枠:Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Steady state trough concentrations will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Clearance
時間枠:Cycle 1 Day 1

Clearance will be calculated using non-compartmental analysis

Cycle 1 Day 1
Accumulation
時間枠:Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Accumulation will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
時間枠:Through study completion, an average of 2 years

Patient-reported outcomes assessed using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS), evaluated as change from baseline at protocol-specified time points. The MPN SAF TSS is a validated questionnaire in which individual symptoms are scored using a numeric rating scale ranging from 0 to 10, with 0 indicating no symptoms and 10 indicating the worst imaginable symptoms; higher scores indicate greater symptom severity.

Through study completion, an average of 2 years
Patient Global Impression of Change (PGI-C)
時間枠:Through study completion, an average of 2 years

Participant reported outcomes assessed using the Patient Global Impression of Change (PGI-C), evaluated at protocol-specified time points. The PGI C is a global assessment scale in which participants rate their overall change in condition since baseline using a 7 point ordinal scale ranging from "very much improved" to "very much worse," with lower scores indicating improvement and higher scores indicating worsening of symptoms.

Through study completion, an average of 2 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年4月29日

一次修了 (推定)

2028年4月1日

研究の完了 (推定)

2028年4月1日

試験登録日

最初に提出

2026年2月26日

QC基準を満たした最初の提出物

2026年3月9日

最初の投稿 (実際)

2026年3月13日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月29日

QC基準を満たした最後の更新が送信されました

2026年10月28日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する